Recursion Pharmaceuticals (RXRX) Revenue & Revenue Breakdown
Recursion Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$58.84M
Latest Revenue (Q)
$5.17M
Main Segment (Y)
License and Service
Recursion Pharmaceuticals Revenue by Period
Recursion Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $58.84M | 32.00% |
| 2023-12-31 | $44.58M | 12.33% |
| 2022-12-31 | $39.68M | 296.81% |
| 2021-12-31 | $10.00M | 193.00% |
| 2020-12-31 | $3.41M | 99.47% |
| 2019-12-31 | $1.71M | - |
Recursion Pharmaceuticals generated $58.84M in revenue during NA 2024, up 32.00% compared to the previous quarter, and up 3438.87% compared to the same period a year ago.
Recursion Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $5.17M | -72.91% |
| 2025-06-30 | $19.10M | 29.56% |
| 2025-03-31 | $14.74M | 226.87% |
| 2024-12-31 | $4.51M | -82.70% |
| 2024-09-30 | $26.08M | 80.91% |
| 2024-06-30 | $14.42M | 4.52% |
| 2024-03-31 | $13.79M | 26.66% |
| 2023-12-31 | $10.89M | 7.81% |
| 2023-09-30 | $10.10M | -8.30% |
| 2023-06-30 | $11.02M | -9.21% |
| 2023-03-31 | $12.13M | -11.28% |
| 2022-12-31 | $13.68M | 4.77% |
| 2022-09-30 | $13.05M | 70.56% |
| 2022-06-30 | $7.65M | 44.42% |
| 2022-03-31 | $5.30M | 111.96% |
| 2021-12-31 | $2.50M | - |
| 2021-09-30 | $2.50M | - |
| 2021-06-30 | $2.50M | - |
| 2021-03-31 | $2.50M | -2.00% |
| 2020-12-31 | $2.55M | 195.94% |
| 2020-09-30 | $862.00K | 363.44% |
| 2020-06-30 | $186.00K | 210.00% |
| 2020-03-31 | $60.00K | - |
Recursion Pharmaceuticals generated $5.17M in revenue during Q3 2025, up -72.91% compared to the previous quarter, and up 35.90% compared to the same period a year ago.
Recursion Pharmaceuticals Revenue Breakdown
Recursion Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|
| License and Service | $58.49M | $43.88M | $39.68M | $10.00M |
| Grant | $351.00K | $699.00K | $162.00K | $178.00K |
Recursion Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: License and Service (99.40%), and Grant (0.60%).
Quarterly Revenue by Product
| Product/Service | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grant | $192.00K | $120.00K | $-73.00K | $48.00K | $303.00K | $267.00K | $431.00K | $1.00K | - | - | $107.00K | $21.00K | $34.00K | $33.00K | $34.00K | $49.00K | $62.00K | - |
| License and Service | $4.98M | $19.10M | $14.82M | $18.91M | $26.08M | $13.49M | $10.62M | $10.10M | $11.02M | $12.13M | $13.68M | $13.05M | $7.65M | $5.30M | $2.50M | $2.50M | $2.50M | $2.50M |
Recursion Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 25: License and Service (96.29%), and Grant (3.71%).
Recursion Pharmaceuticals Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Sep 25 | Jun 25 | Mar 25 |
|---|---|---|---|
| UNITED STATES | $1.11M | $11.79M | $9.48M |
Recursion Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Sep 25: UNITED STATES (100.00%).
Recursion Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| SRPT | Sarepta Therapeutics | $1.90B | $399.36M |
| RCUS | Arcus Biosciences | $258.00M | $26.00M |
| GLPG | Galapagos | $239.70M | $62.43M |
| RXRX | Recursion Pharmaceuticals | $58.84M | $5.17M |
| AGIO | Agios Pharmaceuticals | $36.50M | $12.88M |
| IBRX | ImmunityBio | $14.74M | $32.06M |
| LQDA | Liquidia | $14.00M | $54.34M |
| COGT | Cogent Biosciences | - | - |
| BEAM | Beam Therapeutics | - | - |
| DNLI | Denali Therapeutics | - | - |